Spectral Diagnostics spikes on EUPHRATES trial expansion


Shares of Spectral Diagnostics (TSX:SDI) are up today after the company announced that the Data Safety Board had increased the sample size of its EUPHRATES trial from 360 to 650 patients. “We are pleased with the positive outcome of the second interim analysis,” said CEO Dr. Paul Walker. “The enthusiasm and support from our clinical [...]

Theralase CEO Roger White talks to Cantech Letter

White: "The Theralase PDCs work by destroying only the cancerous tissue and leaving healthy tissue intact. This is why the Theralase anti-cancer technology can be a game changer and disruptive in the war against cancer."

While most of our lives are touched by it, we all know progress in fighting cancer is frustratingly slow. Worldwide, there are 386,000 new cases of bladder cancer diagnosed annually. Yet the standard of care has remained unchanged more than a decade and a half, and no new drugs have been approved for the disease [...]

Robotic surgery hopeful Titan Medical looks to raise $22-million

Titan Medical has invested more than $35-million in its robotic surgery offerings, and will look to commercialize next year.

After a remarkable run that began last November, Titan Medical (TSXV:TMD) today announced it is raising money at a price that is much less dilutive than it would have been last fall. Titan says it has engaged Dundee Securities to sell 10,611,500 units of the company at $2.10 each for total gross proceeds of $22,284,150. [...]

It’s unlikely that Wi-Fi is making us sick, concludes Royal Society of Canada

Royal Society of Canada: ""There is a consensus among these major international reviews that there is no conclusive and strong evidence that exposure to low levels of electromagnetic radiation as stated by the current guidelines would pose any risk of adverse outcomes to humans."

Our increased exposure to electromagnetic frequencies from the recent proliferation of things like wireless local area networks, wireless technologies and smart meters is most likely at safe levels, says The Royal Society of Canada. In a 165 page report prepared for Health Canada entitled “A Review of Safety Code 6 (2013): Health Canada’s Safety Limits [...]

Tweed Marijuana lights up in first day of trading

Tweed Marijuana CEO Chuck Rifici.

Tweed Marijuana (TSXV:TWD) is among Canada’s most actively traded issuers in its first day of trading today. At press time, more than eight-million shares of the Ontario-based company have changed hands. Tweed is one of twelve companies that earned a license to grow medical marijuana through Health Canada. The company raised $30-million through an RTO [...]

Investors follow Paladin’s Goodman to Knight Therapeutics

After selling Paladin Labs, Jonathan Goodman hasn't taken his foot of the pedal. He has now invested Mr. Goodman has invested over $60 million in his latest venture: Knight Therapeutics.

Investors are betting big on former Paladin Labs CEO Jonathan Goodman and his latest pharmaceutical endeavour: Knight Therapeutics (TSXV:GUD). This week, the company closed a $75 million financing, announced a second $75 million dollar round, and then decided to upsize the deal to a staggering $180 million. That gives Knight approximately $240 million on its [...]

Concordia Healthcare to acquire IBS treatment Donnatal


Concordia Healthcare (TSX:CXR) today announced that it would acquire Donnatal® for US$200 million in cash and shares that have a current market value of (U.S.) $65.3 million. Privately held specialty pharmaceutical company Revive Pharmaceuticals (not to be confused with Revive Therapeutics Ltd. (TSXV: RVV), a clinical-stage company developing novel therapies for gout, sleep apnea and [...]

Is BioSyent The Next Paladin Labs?

Biosyent's leading brand is FeraMAX. It currently markets two formulations for the treatment of iron deficient anemia.

It was around 1999, and I was a pharmaceutical sales rep with Fournier Pharma, when I bumped into my first Paladin Labs sales rep at a physician’s office. I had never heard of Paladin Labs and was shocked to see the number of products the rep was carrying in their sample bag. It was industry [...]

How Tekmira Became Canada’s Hottest Biotech Stock

In January 2014, a perfect storm of positive corporate, industry, and investor validation occurred that has rewarded Tekmira with a surging valuation...

Tekmira (TSX:TKM, Nasdaq:TKMR) has always had a compelling story -the company is a pioneer in a exciting new area of medicine with best-in-class technology -but until very recently it lacked a broad investor audience. In late 2013, however, the company made some strategic decisions that helped grow its investor appeal greatly and turned the stock [...]

Canadian Biotech Stocks: The Ten Best Performers So Far in 2014

Burnaby's Tekmira has become a world lead in RNA interference, a process that cells use to silence the activity of specific genes.

In the U.S., biotech stocks partied like it was 1999 last year, delivering a spike that was second only to that year’s 102% gain. But Steve Silver, a biotech analyst at S&P Capital IQ, says the long overlooked sector isn’t overvalued. “The extent to which these companies have gone up this year would suggest that [...]